Roche has agreed a deal to acquire US biotech Carmot Therapeutics that, if consummated, will thrust it into the increasingly competitive market for incretin-based therapies for diabetes and obesity.

Switzerland's Roche announced a US$2.7 billion deal to acquire US weight-loss drug developer Carmot Therapeutics, challenging Denmark's Novo Nordisk and Eli Lilly (LLY.US) ... Roche said the ...

Roche has reported early clinical data with its candidate obesity therapy CT-388, bought as part of its $3.1 billion takeover of Carmot Therapeutics that was announced last year. A phase 1b trial ...